Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing.
Joseph B HiattHolly SandborgSarah M GarrisonHenry U ArnoldSheng-You LiaoJustin P NortonTravis J FriesenFeinan WuKate D SutherlandHugh Young RienhoffRenato MartinsA McGarry HoughtonShivani SrivastavaDavid MacPhersonPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
LSD1 inhibition increased MHC-I expression and enhanced responses to PD-1 inhibition in vivo, supporting a new clinical trial to combine bomedemstat with standard-of-care PD-1 axis inhibition in SCLC.